Αρχική World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy... World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC Από Ogkologos - 29 Ιουλίου, 2026 193 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR News digest – larger waistlines and prostate cancer, GP gut instincts... 5 Σεπτεμβρίου, 2020 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer 2 Ιουλίου, 2024 Mediterranean Diet Associated with a Higher Probability of Response in Patients... 28 Φεβρουαρίου, 2023 EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide 10 Αυγούστου, 2020 Φόρτωση περισσοτέρων HOT NEWS How People With Cancer Can Make the Most of Televisits ‘Dance Moms’ Star Abby Lee Miller Opens Up About Her Cancer... ESMO Congress 2023, 20-24 October 2023 Madrid, Spain EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine